Efficacy of canakinumab in a patient with adult-onset glucocorticoid-resistant periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome

• Published in: Modern rheumatology case reports Vol. 7; no. 1; pp. 276 - 279
• Main Authors: Sopeña, Bernardo, Araújo, Olga, Freire, Mayka, Barrera-López, Lucía, Hernández-Rodríguez, José
• Format: Journal Article
• Language: English
• Published: England 03.01.2023
• Subjects: Adult; Amyloidosis; Child; Colchicine; Fever - drug therapy; Fever - etiology; Glucocorticoids; Humans; Joint Diseases; Lymphadenitis - diagnosis; Lymphadenitis - drug therapy; Pharyngitis - drug therapy; Pharyngitis - etiology; Stomatitis, Aphthous - diagnosis; Stomatitis, Aphthous - drug therapy; Syndrome; anakinra; canakinumab; PFAPA syndrome; anti-interleukin-1 treatment; autoinflammatory diseases
• ISSN: 2472-5625; 2472-5625
• DOI: 10.1093/mrcr/rxac043

Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome, a polygenic or multifactorial condition, is the most frequent autoinflammatory disease in children. There is increasing evidence that some patients may have a disease onset during adulthood. With regard to PFAPA syndrome treatment, single medium-to-high doses of glucocorticoids during flares constitute the therapy of choice in children and adults, colchicine may be useful in some patients, and tonsillectomy has been reported of utility mainly in paediatric patients. Interleukin-1 (IL-1) blockers have been sporadically used with good response in glucocorticoid-resistant cases. We report a patient with an adult onset of glucocorticoid-resistant PFAPA syndrome and inconsistent response to colchicine and anakinra, who later achieved a complete and sustained response to canakinumab. Although canakinumab seems to be a good therapeutic option in paediatric and adult patients with refractory PFAPA syndrome, the best anti-IL-1 agent and the sequence of administration have to be still determined in well-designed clinical trials.